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The availability of high-throughput genotyping technologies and microarray assays has allowed researchers to consider pursuing investigations
whose ultimate goal is the identification of genetic variations that influence levels of gene expression, e.g., “expression quantitative trait locus” or
“eQTL” mapping studies. However, the large number of genes whose expression levels can be tested for association with genetic variations in
such studies can create both statistical and biological interpretive problems. We consider the integrated analysis of eQTL mapping data that
incorporates pathway, function, and disease process information. The goal of this analysis is to determine if compelling patterns emerge from the
data that are consistent with the notion that perturbations in the molecular physiologic environment induced by genetic variations implicate the
expression patterns of multiple genes via genetic network relationships or feedback mechanisms. We apply available genetic network and pathway
analysis software, as well as a novel regression analysis technique, to carry out the proposed studies. We also consider extensions of the proposed
strategies and areas of future research.
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consequences of DNA sequence variation has been greatly
enhanced as a result of the introduction of high-throughout,
multiplex technologies such as gene expression microarrays,
proteomics technologies, and metabolomic assays. A number of
studies have been pursued recently that have shown that
naturally occurring DNA sequence variations in a wide variety
of organisms influence the levels of the expression of particular
genes [1–6]. This is not surprising given that DNA sequence
variations, such as single-nucleotide polymorphisms (SNPs) or⁎ Corresponding author. Polymorphism Research Laboratory, Department of
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doi:10.1016/j.ygeno.2007.03.003deletions, in gene regulatory regions of the genome, such as
promoters, could, e.g., influence the ability of a transcription
factor to bind and thereby affect the activity of a promoter
guiding the transcription of a gene.
Many studies examining the relationship of DNA sequence
variations and gene expression levels have not actually
considered the biological mechanisms behind such relation-
ships, but have rather focused on the mere association between
sequence variations and gene expression patterns in an effort to
make broad claims about the roles of likely cis-regulatory vs
trans-regulatory factors in mediating gene expression on a
genome-wide scale. These studies, known as expression
quantitative trait locus (“eQTL”) mapping studies or “genetical
genomic” studies, have shed enormous light on the global role
of sequence variation in mediating gene expression [1–8].
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with the expression level of a gene—whether or not that
sequence variation resides within the gene whose expression
level is influenced—ultimately raises a number of questions
about the relationships of the associations themselves. For
example, one could ask if the genes whose expression levels are
influenced by a particular genetic variation appear to be
involved in the same genetic network, process, or pathway.
Addressing such questions could lead to the characterization of
genetic variations that influence entire processes and raise the
possibility that one of the genes that is influenced by the
sequence variation in question is more upstream in the network
or process of relevance. Thus, one could infer that a perturbation
in a particular gene induces a cascade of physiologic events that
affects all, or many, of the other genes in a particular network or
process.
The reason this type of analysis is important is obvious: it is
very unlikely that the expression level of a single gene, when
perturbed by a single naturally occurring DNA sequence
variation, will induce an overt clinically identifiable or
physiologically meaningful phenotype, given the fact that
genes operate in networks replete with redundancy, feedback,
and compensatory mechanisms. In fact, it is well known that
most traits or diseases are multifactorial and complex
genetically, whereby many genes and/or environmental factors
are responsible for their expression.
We have therefore considered the analysis of published
eQTL mapping studies involving humans that takes into
account the possible participation of genes in various networks,
pathways, diseases, or drug targets, whose expression values
appear to be influenced by particular SNPs. The goal of the
analysis is to determine if it is possible to make sense of the
collection of genes whose expression patterns are influenced by
an individual SNP or a group of SNPs. In this light we address
two related questions: (1) are the genes whose expression
patterns appear to be associated with a particular SNP involved
in a particular known process or network? and (2) do the genes
whose expression patterns appear to be associated with different
SNPs have any commonalities? Or rather, do some sets of SNPs
(working either in cis- or in trans-acting fashions) influence the
expression levels of genes in the same pathway or network?
Although a number of studies have been undertaken in
humans to identify genetic variations influencing the expression
levels of genes [1–3,9,10], we have concentrated on the analysis
of 28 SNPs (24 SNPs chosen for their association with gene
expression and 4 randomly chosen SNPs not known to affect
expression levels, which we have chosen to act as ‘“controls”)
and expression data on 8523 genes obtained by Cheung et al. [1]
due to its recognition by the scientific community, the
availability of the data, and the fact that we have considered
these data in particular candidate gene analyses [11] as well as
in genome-wide association studies (J. Wessel, O. Libiger, N.J.
Schork, submitted for publication). To carry out the analysis, we
took advantage of Ingenuity’s Pathway Analysis software [12]
as well as a novel multivariate analysis technique that can be
termed “multivariate distance matrix regression” (MDMR)
analysis, which has been shown to have utility in the analysis ofhigh-dimensional gene expression and SNP data [11,13,14] (C.
Ye, M.A. Zapala, H.M. Kang, J. Wessel, E. Eskin, N.J. Schork,
submitted for publication).
Results
Individual gene results
Univariate association analyses involved each SNP we chose
to study as well as the available gene expression data, resulting
in 28×8523=238,644 analysis results (the results of these
analyses are available from the authors). We ranked the p values
associated with the analysis of each gene expression variable for
each SNP. The genes whose expression values were most
strongly associated with each SNP were then used in the
pathway analysis. We used an arbitrary p-value cutoff of
p<0.05 to identify genes whose expression values were
“associated” with each SNP. We chose this value to avoid
false negative results, but we recognize that it might result in
false positive results as well. We therefore evaluated the utility
of this p<0.05 criterion via power and expected discovery rate
calculations, as described below. Table 1 provides the results of
the analyses for each individual SNP using the Ingenuity
software package as described under Materials and methods.
Table 1 includes, for the sake of space limitations, only the top
10 diseases, functions, and canonical pathways (ranked by p
values) that were overrepresented among the genes whose
expression values were associated (p<0.05) with each SNP. The
drug targets listed are those represented in the top scoring
network for each SNP. The abbreviations used in Table 1 are
listed in the appendix.
Power studies
We determined the expected discovery rates (EDR), the
probability of a true positive (PTP) result, and the probability of
a false positive (PTN) result based on the 8523 univariate gene
expression analyses performed for each SNP using the
strategies described by Page et al. [15] and Gadbury et al.
[16], as implemented on the PowerAtlas Web site [17]. This
analysis provided us with insights as to the strength of the
associations between the SNPs that Cheung et al. [1] identified
as significantly associated with not only the expression levels of
the particular genes reported in their paper, but also the
expression levels of the other genes they assayed. Table 2
provides the results of the analyses as well as the percentage of
genes whose expression levels were significantly associated
(p<0.05 and p<0.01) with the SNPs. Note that because of the
number of statistical tests performed, we also presented results
at the more conservative cutoff of p<0.01 just for the sake of
comparison. For the 24 SNPs Cheung et al. [1] identified as
highly associated with the expression level of a particular gene,
the most consistently high PTP (≥0.8) and EDR (≥0.4) at
p<0.05 observed were found for SNPs with designations
rs10490570, rs10509846, and rs9600337. Many of the other
“associated” SNPs described by Cheung et al. [1] had moderate
values of PTP or EDR (0.15–0.79) when a p value of p<0.05
Table 1
(A) Gene expression analysis results assuming functional, disease, pathway, and drug target groupings of the genes whose expression levels were significantly associated with each SNP
Phenotype: DDX17 VAMP8 CTBP1 ICAP-1A TM7SF3 CTSH RPS26 IRF5 S100A13 CPNE1
Probe ID: 208151_x_at 202546_at 203392_s_at 203336_s_at 217974_at 202295_s_at 217753_s_at 205469_s_at 202598_at 206918_s_at
SNP rs No.: rs10490570 rs10509846 rs1060043 rs10807387 rs11822822 rs1369324 rs2271194 rs2280714 rs3757791 rs6060535
Functions ACCPLCL OPMP IG SS FcT TSf1BS ADTL QCIB MD DSCGN
DMt IL SGC RAA SN ASF1RE ADC QC IN PA
PSC TIL4RE OPMP HSC ApM CkCL ADT QAA FPp RgT
SRS ITL Mas IRM OGP DCa CGIBCL GOC CMBL AAT
HtM EH RTt FxCl SCCTC DHN CLDNA SCA CMKCL QM
MFb CBF DATP RL CCPMCL DSC DS ACC ADL DGT
DpC EDC IE ECa HGDP EjM OWPO AdO MAPC ACAM
CDGC CB TV HPd QEC MF RcDNA CNKTL STS QMPC
DGC Wnt/BCS ACCPLCL SDG LL Q12SHA CGIECL CNKTL QCP FlT
EmRNA IBL RSP CMGC ASTATRE DPG BH DDEP QLT TBc
Diseases DTCL CLCCL CRPCL CVD ANKTL AOMS ICT HDR HCH EB
EdH CLkCL IsM ABCCL AR EmH ICC LO AOMS GABEB
DDHV XLMR ApTCL Sz H GA PT DCVT IHPC ApMb
IFCL Ht IO AtTCL CDLCL HDH PcC DN KF EBS
VLC HpCL NMC LBC APC XPCGE VIP AJ LH LoBC
FT FO GsM S AF DAN HFC QPC LN MMGT
HLV FTCL ADP WLR ANB HR HEG DC CDSCC BM
AS IT NC HF AG1PTTCL TCC BAC DR MSM CFCL
EOMO AS DbM E AISCCL IC IvTL DCCL ADHD CRBC
FD EAEM ALCL AMC DfM HTg HDC MTTCL CCaC DO
Pathway PTENS CCC CCG2/M Wnt/BCS NGB IL4S ButM CaS OCPF PTTB
PI3K PPARS PPARS CCC AP IL2S VLID PheM SRS ERSP
XMS TyrM ASM GPCRS NERP BAS PyrM
GB NOSCVS PDGFS FAM LD
SRS GD RM GPM
PPARS p38MAPKS FAB2 OGB
IL10S DGDGM LD CCC
PD SDKB PS
EGFS PM PM
IGF1S TM
Drug targets Cg Cg None ADAT 6RT ATAC Est CTA IDN DAAT
NR DS RDT PE1 EIT DAAT CADV Cg
SBAV ST UV IDN BFNT FP
TPI NZ IT
ZK PVF INO
RDT OT
YM
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(B)
Phenotype: S100A13 CPNE1 TCEA1 IL16 SMARCB1 EIF3S8 CSTB CHI3L2
Probe ID: 202598_at 206918_s_at 216241_s_at 209827_s_at 212167_s_at 210949_s_at 201201_at 213060_s_at
SNP rs No.: rs3757791 rs6060535 rs6562160 rs6957902 rs7802273 rs8092794 rs880987 rs755467
Functions MD DSCGN ISRE TCT QCFEC CPBM AMt MCC
IN PA APMP BP APTP SLE QN APPC
FPp RgT JDNAF SP RCAMP CMPBL M DHT
CMBL AAT QTC FuL CSC CMp CA FP
CMKCL QM CCH TB TRunx2 CaMo DDSE MC
ADL DGT HRDNA BF BOLA MCm ECRE AHNF4
MAPC ACAM CmRNA FuP LLs CMTL FTM RCt
STS QMPC DRG IDNA TCA TPR MSMC RCP
QCP FlT AWAT TET CR CMc NRGC QOF
QLT TBc AAtf1BS BMt LR ICTL SRM DSS
Diseases HCH EB SBCCL K HTN IHIV1 CVCCCL PIN
AOMS GABEB TF CMMTC PTTCL CLCL ARMCL DE
IHPC ApMb GS MMTC HGC CMLCL ASGC DOP
KF EBS FIT ICCCL ABL E AT MCCL
LH LoBC RgC EN CHCL APCCL CGICCCL PSCD
LN MMGT AnT ASMC FHC ARBS MDV PINM
CDSCC BM SCCL ACCCL SSCCL CAAM Hc PINM
MSM CFCL GBC CGICvC CVD CAAM HtM Hg
ADHD CRBC PPCCL DDMD DDG CSNB1 HSS ApO
CCaC DO ApEC DA FCNHL EM LN ApSc
Pathway OCPF PTTB CysM CysM SB GRS Wnt/BCS AtRNAB
SRS ERSP PDGFS VEGFS CC cAMPMS UB ERS
PyrM EGFS PTTB BGGBN CS TGFBS
LD NOSCVS CaS BAM PurM
GPM AP CCG1/S GSTM
OGB FAB2
CCC VEGFS
PS E/M
PM N/TrkS
Drug targets IDN DAAT RF DACA Ac A Est BP
Cg NCF MAD AFD DAAT MH
FP NR AVP AVPL
IT PTR CL BFNT
INO PVF KC
OT SISB
YM
(continued on next page)
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Table 1 (continued)
(C)
Phenotype: PPAT PPAT LRAP HSD17B12 PSPHL HLA-DRB2 AA827892 CGI-96
Probe ID: 209433_s_at 209433_s_at 219759_at 217869_at 205048_s_at 209480_at 65588_at 33307_at
SNP rs No.: rs2139512 rs227940 rs2762 rs4755741 rs6593279 rs6928482 rs788350 rs9600337
Functions Ct DPG TMA QIP CDNA DBMD ECL BBCL
QC BTL IL RMD MI GMC PCL CCPBCL
CEkC PHITL QPBL QBE MA CVESC DBCL RP
HEC QC2 CFPBL ATI ADPRAA RO AB FSR
RSMC BBrCL ITL AKC CL StBMC BCD28R ARNA
HCL ON GOC SC HTb UPRC DDLSC ACCPCL
Mca QC QPD SBF MP MN FAA CTm
SE CBV FcL ATL PL SBL LTL Q12HA
RC DvS QGMPC EESC SMXC CFCFUM RLC BLCL
REC GPSC RSMC FEF DAF ELP TCD28 ITP
Diseases IDS HpCL DBBB RT PC HDC PC GPT
InfS CHB HpCL TLCCL ACPBCL RUD PBCCL BCC
PH HBCL PMNM TO QSC HTgR ETCL FC
TAPC NSCLC HBCL HiM PCn RUDM ASCCL GLCCL
AICL AVB PR C EGT P CSCCL GC
DNCL AM IF G2/MP GP FO DST ATCL
AECL SADM PdL IICL LBBB F ILCL GMT
Ha HDC SL LB SCLL FL HBMC ALCCL
BA N AgTCL MFCL TC ApMC Dac AO
DNDM CVCRCCL AgBCCL OB SM HDEC DHCL MLCCL
Pathway GPM GPM AP CaS IRS Wnt/BCS NS FAB1
BGGBN NKCS PI3K IL6S FAB1 ES TCRS IS
PD PTENS GSTM BAS BCRS PI3K
IRS MM IL4S IM SAPK/JNK
GluM ASM GMCSFS SHS
NgM SM CCG1/S
SRS XMS OCPF
CBAS BCRS
NOSCVS E/M
AP FGFS
Drug targets AET Est EMD FCTF EPB IMSR CaT LY
AVP AS EZ FP IDN PT EDA
DP CTA IGF1 XV INO FD
DAA EZ TH PVF GC
TAK IGF1
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(D) Control SNPs
Phenotype: CXCL11 RIPK1 PLSCR1 PLSCR1
Probe ID: 210163_at 209941_at 202446_s_at 202446_s_at
SNP rs No.: rs10017431 rs10498658 rs2688692 rs2587021
Functions CCL PBC Ej DH
CECL CTh2L PCCL RH
CNTCL AEC AgEC AN
NPC TOA BATRE DGC
BmRNA CAC CEC Ej
MLC EAC EE TTDNA
QIJ G0/SPT PPF RPA
PcP GUBC SBV G
AECC PP AN DD
CGJ CNKC DGC RGFAA
Diseases DMC RTCL MLCL ARVD
HpC ASCCCL U VTH
HAM IvLCL AxR El
IEC MHCL AxM IDDMM
GnM RCCCL HS AxR
EP HB IK AtR
NM HCb FHM CMG
PcR JRA CM CDO
SADM MGC CMCC Hm
Hp SCTCL AlR VT
Pathway IFS AtRNAB CS GABARS
PTTB VEGFS AAM
SCLB cAMPMS cAMPMS
FAB2 ES
Drug targets Est FP Ac RS
AAH IG1B CB SR
BR SM EZR TG
IM NN
IMSR RZ
OM TH
RGPT
Phenotype is the gene whose expression values were most significantly associated with the SNP listed in the third row based on the analysis by Cheung et al. [1]; groups that were significantly overrepresented among the
genes whose expression values were associated with each SNP are listed with p<0.05, normal font; p<0.01, italic; p<0.001, bold; and p<0.0001, bold and italic. Probe ID is the Affymetrix ID for the gene expression
transcripts. Abbreviations used are listed in the appendix.
Control SNPs were not significantly associated with their local genes in t tests.
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Table 2
Probability of true positive and expected discovery rate analysis of gene
expression associations with each SNP
SNP rs No. No. with p<0.05 PTP EDR No. with p<0.01 PTP EDR
Associated SNPs
rs10490570 1117 (13.1) 0.8 0.8 568 (6.7) 0.94 0.7
rs10509846 1081 (12.7) 0.84 0.65 337 (4.0) 0.95 0.44
rs1060043 834 (9.8) 0.57 0.32 197 (2.3) 0.65 0.09
rs10807387 1126 (13.2) 0.71 0.43 391 (4.6) 0.85 0.19
rs11822822 724 (8.5) 0.28 0.14 150 (1.8) 0.25 0.14
rs1369324 560 (6.6) 0.45 0.29 146 (1.7) 0.68 0.16
rs2271194 400 (4.7) 0.02 0.01 94 (1.1) 0.01 0
rs2280714 535 (6.3) 0.59 0.12 124 (1.5) 0.71 0.04
rs3757791 553 (6.5) 0.41 0.63 187 (2.2) 0.73 0.48
rs6060535 519 (6.1) 0.25 0.35 134 (1.6) 0.44 0.16
rs6562160 753 (8.8) 0.46 0.22 188 (2.2) 0.5 0.05
rs6957902 1051 (12.3) 0.51 0.19 281 (3.3) 0.52 0.04
rs7802273 1371 (16.1) 0.77 0.38 509 (6.0) 0.87 0.14
rs8092794 746 (8.8) 0.63 0.51 247 (2.9) 0.83 0.3
rs880987 662 (7.8) 0.35 0.16 176 (2.1) 0.36 0.04
rs755467 466 (5.5) 0.07 0.1 110 (1.3) 0.04 0.01
rs2139512 799 (9.4) 0.38 0.15 208 (2.4) 0.34 0.02
rs227940 373 (4.4) 0.04 0.01 67 (0.8) 0.01 0
rs2762 319 (3.7) 0.18 0.01 56 (0.7) 0.09 0
rs4755741 657 (7.7) 0.57 0.69 245 (2.9) 0.84 0.56
rs6593279 466 (5.5) 0.17 0.06 101 (1.2) 0.16 0.01
rs6928482 628 (7.4) 0.51 0.32 177 (2.1) 0.69 0.14
rs788350 541 (6.3) 0.32 0.43 145 (1.7) 0.56 0.23
rs9600337 1358 (15.9) 0.87 0.76 597 (7.0) 0.96 0.6
Random SNPs
rs10017431 379 (4.4) 0 0 82 (1.0) 0 0
rs10498658 413 (4.8) 0 0 80 (0.9) 0 0
rs2688692 322 (3.8) 1 0.02 51 (0.6) 1 0
rs2587021 253 (3.0) 1 0.01 34 (0.4) 1 0
No. with p<x is the number of genes whose association strength with the SNP
designated in the leftmost column produced a p value less than x (numbers in
parentheses designate the percentage of the total number of genes with p<x);
PTP is the probability of a true positive result; EDR is the expected discovery
rate.
138 J. Wessel et al. / Genomics 90 (2007) 132–142was used to assess significance. We note that some of Cheung et
al.’s [1] “associated” SNPs had low PTP and EDR values (e.g.,
rs2271194 and rs227940), suggesting that either the associa-Fig. 1. Example power analysis of the SNPs rs10490570 and rs10017431 reporting the
size using the methods associated with the PowerAtlas Web site (www.poweratlas.o
discovery rate is reflected by the dotted line, and the probability of a true negative rtions those SNPs had with gene expression values were literally
confined to one gene (or a very small number of genes) or the
results were likely to be false positives. At p<0.01 the PTP
increased for 70.8% (17) of the SNPs, while the EDR decreased
for all of the SNPs. The 4 control SNPs (i.e., SNPs not identified
by Cheung et al. [1] as having any strong association with any
single gene’s expression values) showed either an EDR or a
PTP of 0 (at either p<0.05 or p<0.01). Fig. 1 provides a
graphical display of the PTP, EDR, and PTN as a function of
sample size based on one of Cheung et al.’s [1] associated SNPs
(rs10490570) and one of our control SNPs (rs10017431).
Individual SNP pathway analysis
We report up to 10 of the significantly overrepresented
functions, diseases, canonical pathways, and drug targets, as
defined in the Ingenuity software, for each of the 28 SNPs in
Table 1. There are 611 unique “networks” involved in canonical
pathways, functions, or disease processes queried in the
Ingenuity software. For functions and diseases, there were
usually more than 10 significantly overrepresented networks for
each SNP, but for the canonical pathways only 14.3% of the
SNPs had fewer than 10 that were significantly (p<0.05)
overrepresented. The most significantly overrepresented net-
works for the SNPs were associated with a number of diseases
or particular biological functions; for example we found that for
SNP rs6928482 there were 628 genes whose expression levels
differed significantly across genotypes (p<0.05). Of these 628
genes, 6 were involved in cellular hematological disorders and
14 were involved in the Wnt/β-catenin signaling pathway.
Combined SNP analysis
Two pathways were the most frequently represented among
the genes whose expression values were associated with the 28
SNPs we analyzed. These were the Wnt/β-catenin signaling
pathway (common to the gene expression levels significantly
associated with 4 of the 28 SNPs) and the serotonin receptortrue positive, true negative, and expected discovery rates as a function of sample
rg). The probability of a true positive is reflected by the solid line, the expected
esult is reflected by the dashed line.
Table 3
Multivariate distance matrix regression analysis of SNPs influencing the serotonin receptor and the Wnt/β-catenin signaling pathways
Pathway SNP Marginal results Conditional results
p value % variation p value % variation Cumulative
Serotonin receptor signaling rs2139512 0.0109 5.0 0.0109 5.0 5.0
rs10490570 0.0294 4.1 0.0311 3.8 8.8
rs3757791 0.1934 2.5 0.5421 1.4 10.2
Wnt/β-catenin signaling rs10807387 0.0008 5.0 0.0008 5.0 5.0
rs10509846 0.1350 2.5 0.1118 2.5 7.4
rs880987 0.4037 1.8 0.2318 2.1 9.5
rs6928482 0.2185 2.2 0.4961 1.6 11.1
Marginal results, an analysis of each SNP tested independently; Conditional results, forward stepwise regression results; % variation, percentage of variation in the
similarity matrix explained by the SNP; Cumulative, cumulative percentage of variation explained by the SNP(s).
139J. Wessel et al. / Genomics 90 (2007) 132–142(SR) signaling pathway (also common to 4 SNPs). In addition,
the Wnt/β-catenin signaling pathway was the most significantly
associated “canonical” pathway for 3 of the SNPs. Of the genes
in the Wnt/β-catenin signaling pathway, between 8 and 25 of
them were significantly associated with the 4 SNPs (p<0.05)Fig. 2. An example of a group of genes common to the Wnt/β-catenin signaling pat
orange represent the genes whose expression is influenced significantly (p<0.05) bfor which this pathway was overrepresented. Many others of
these genes overlapped across 2 or 3 of these 4 SNPs, while
some were unique to a particular SNP. We then identified 50
Wnt/β-catenin signaling pathway genes whose expression
levels were associated with at least one of these 4 SNPs andhway influenced by a particular SNP (rs10807387). The proteins highlighted in
y rs10807387.
Table 4
Multivariate distance matrix regression analysis with the subset of genes
associated with each SNP influencing the Wnt/β-catenin signaling pathway
SNP
associated
with subset
of genes
SNP Marginal results Conditional results
p
value
%
variation
p
value
%
variation
Cumulative
rs10509846 rs10509846 0.0369 4.59 0.0321 4.54 9.26
rs10807387 0.0356 4.71 0.0356 4.71 4.71
rs10807387 rs10807387 0.0001 6.9 0.0001 6.9 6.9
rs880987 rs880987 0.0108 4.94 0.0108 4.94 4.94
rs6928482 rs6928482 0.0084 5.29 0.0084 5.29 5.29
All four SNPs were used in analyses, but only significant SNPs are shown.
Marginal results, an analysis of each SNP tested independently; Conditional
results, forward stepwise regression results; % variation, percentage of variation
in the similarity matrix explained by the SNP; Cumulative, cumulative
percentage of variation explained by the SNP(s).
140 J. Wessel et al. / Genomics 90 (2007) 132–142used them to form a Euclidean-distance/similarity matrix for the
MDMR analysis (see Materials and methods). The MDMR
analysis suggested that one of the 4 SNPs was strongly
associated with expression levels of these 50 genes when these
genes were considered as providing multivariate gene expres-
sion profiles (i.e., when they were considered jointly and not as
single gene expression levels assessed individually; Table 3;
p=0.0008). This SNP explained 5.0% of the variation in the
similarity/dissimilarity of the expression profiles of these 50
genes across the subjects (Table 3). In individual univariate
analyses involving genotype categories for this SNP (i.e.,
rs10807387) and each of the 50 gene expression levels, the p
values ranged from 0.0007 to 0.99, with the expression levels of
the WNT2 gene being the most significantly associated with
this SNP. Fig. 2 is an example of a group of genes influenced by
a particular SNP (rs10807387) involved in the Wnt/β-catenin
signaling pathway.
When the similarity analysis involved multivariate expres-
sion profiles constructed with only those genes whose
expression values were significantly associated with at least
one of the four individual SNPs based on univariate analyses,
the results improved (only significant results shown, Table 4).
Two SNPs were actually found to be associated with the
similarity of the expression profiles of these genes (Table 4);
however, only one gene (LRP5) was associated with both SNPs
from univariate analyses. For the SR signaling pathway, three
SNPs were identified as being associated with this pathway and
involved the expression levels of 4–8 genes (14 in total). Two
SNPs were associated with the expression levels of the 14 genes
involved in the SR signaling in univariate and multivariate tests
and explained 8.8% of the variation (Table 3).
Discussion
We have shown that a comprehensive, pathway-oriented
analysis of eQTL mapping data can lead to more compelling
insights about the relationships of DNA sequence variations and
gene expression levels. It is well known that genes participate in
networks and do not function in isolation. It is therefore
important to consider this fact when evaluating the ultimatesignificance of the impact of sequence variation on the
expression levels of multiple genes. We find that many of the
SNPs shown to be strongly associated with the expression levels
of particular genes by Cheung et al. [1] are also associated with
the expression levels of many other genes and that the reason
the SNP might be associated with these other genes’ expression
levels is the fact that those genes participate in common sets of
biological processes or pathways.
We also find that many SNPs—some of which were
identified as significantly associated with particular gene
expression levels by Cheung et al. [1] —do not appear to be
associated with the expression levels of genes participating in
common pathways. This suggests that either the SNP affects the
expression level of a gene whose influence is nonessential for a
particular process (i.e., it is compensated for easily or is
peripheral to the activities of that process) or the original
association is likely to be a false positive result.
Our assessment of the likely EDR and PTP result for each
SNP also sheds light on the utility of pathway analyses in eQTL
analysis. We find that many of the SNPs found to be
significantly associated with the level of the expression of a
particular gene by Cheung et al. [1] did not yield strong
associations with other genes and hence had very low expected
discovery rates and probabilities of true positive results.
Examples include SNPs rs2271194 and rs2762, which Cheung
et al. [1] found to be highly associated with the expression
levels of the RPS26 (p=7.94×10−12) and LRAP (p=1.98×
10−19) genes, respectively, but had very low EDR and PTP
values (EDR=0.01 for both and PTP=0.02 and 0.18,
respectively). This analysis calls into question the actual
influence of these SNPs on gene expression patterns despite
their strong association with the expression levels of a single
gene. We want to emphasize that our use of a common p value
(i.e., p<0.05) for declaring significance of an association
between each SNP and the 8523 gene expression levels may not
have been ideal. Rather, it might be advantageous in analyses
like the one we have pursued to use different thresholds for each
gene based on, e.g., EDR and PTP analysis, to generate the list
of genes to be interrogated in the pathway and common process
analysis. Our analysis of the influence of a SNP on an entire
pathway via MDMR also shows promise in this regard, in that
we were able to show that particular SNPs appeared to influence
the entire expression profile of a group of genes known (or at
least likely) to participate in a particular process or pathway.
Our analyses of processes, diseases, and pathways demon-
strate the heterogeneity of functions and diseases that a
polymorphic locus can influence. We did find, however, some
loci that appear to influence a limited number of networks; for
example, rs6060535 was found to be associated with only two
pathways, which may be tightly regulated pathways or
pathways with fewer genes involved. The functions we
considered generally produced smaller p values than the disease
categories, possibly due to the number of genes involved in
either. This could also simply reflect limitations in the Ingenuity
knowledge base regarding disease processes.
There are a number of important issues and directions for
future research that should receive special attention. For
141J. Wessel et al. / Genomics 90 (2007) 132–142example, our analysis is entirely dependent on the veracity and/
or completeness of the available knowledge base(s) of
biochemical processes and gene interactions (in our case, the
knowledge base developed by Ingenuity). Likewise, we used a
liberal threshold (p<0.05) to compile our gene list for network
analysis, and a more statistically robust list could lead to a more
refined list that reflects the biologically relevant effects of the
SNPs. In addition, in all our analyses we took individuals,
categorized by genotype at SNP loci, as our units of
observation, with the expression levels of the genes taken as
multivariate “phenotypes” observed on those individuals. Other
studies consider the expression levels of genes as the units of
observation to draw inferences about the connections between
genes [18]. We feel that it is more natural and scientifically
correct to consider individuals categorized by genotype as the
unit of observation and the correlations among the expression
profiles of the genes as simply reflecting biological/physiolo-
gical realities of interest that can be worked out via data
analyses like ours.
Finally, it is unclear if our analysis of expression patterns
observed in immortalized lymphocytes truly correlates with
activities and functions in vivo, as it is well known that the
expression levels of genes are tissue-specific and possibly
influenced by immortalization and transformation [19,20].
Despite these caveats, our analysis has promise. It may be
possible that in the future, as more and more eQTL mapping
studies are pursued and knowledge of the interaction of genes
grows, one could work out—using purely computational
methods—the regulatory machinery associated with not just
individual genes, but entire networks, pathways, or processes
likely involved in molecular physiologic phenomena and events.
Materials and methods
CEPH gene expression and SNP data
We used data from the study pursued by Cheung et al. [1,21], which included
gene expression data representing 8523 unique genes on 57 CEPH-repository-
derived individuals whose genomic DNAwas studied for polymorphism as part
of the International HapMap Project [22]. We note that we actually examined the
expression levels of 8672 probes, but some of these probes interrogated the same
gene. The HapMap research produced approximately 1.5 million genotypes on
these 57 individuals. Cheung et al. [1] identified strong associations between
particular SNP locus variations and the expression values of particular genes for
24 SNPs (referred to here as “associated” SNPs) as described in Table 1 of
Cheung et al. [1]. In addition to these 24 SNPs, we included in our analyses 4
randomly chosen SNPs as controls, since these SNPs were not found to have
strong associations with the expression values of any genes. The additional
SNPs had RS numbers of rs10017431, rs10498658, rs2688692, and rs2587021.
Univariate gene expression analysis
Analysis of the relationship of the expression level of each gene to each SNP
was performed by testing the equality of expression levels across genotype
categories using univariate analyses that included traditional t tests and the
nonparametric Mann Whitney U test [23]. Some of the 28 SNPs had very
unequal allele frequencies and hence had no or only a few individuals with a
particular homozygous genotype. Due to this fact, the rarer homozygote and the
heterozygote were combined, creating two genotypic categories that could be
contrasted for gene expression differences. Results from the traditional t tests of
the association between the dominant genotypes and gene expression levelswere used for the rest of the study. Results from the Mann Whitney U test were
compared to the traditional t tests for consistency in the p values.
Power studies and false discovery rates
We used the techniques described in the paper and Web site associated with
PowerAtlas [15–17], which describes tools designed for microarray data
analysis power calculations. The techniques described in the paper and
implemented on the Web site were used to estimate the PTP, the PTN, and the
EDR of the 8523 gene expression analyses involving contrasts across the
genotype categories for the 28 SNPs. The PTP is defined as the proportion of
genes that are declared significantly differentially expressed between two
groups, a concept similar to the false discovery rate. The EDR is the average
power for all genes for which the null hypothesis is false in an experiment or, in
other words, the proportion of genes that are differentially expressed that will be
declared as such. For each of the 28 SNPs, we report the estimated PTP and EDR
at a significance threshold of 0.05 and 0.01.
Pathway analysis
Weused the Ingenuity pathway analysis software package [12] to analyze and
assess sets of functions (Gene Ontology terms), canonical pathways, diseases,
and drug targets overrepresented in the lists of genes whose expression levels
were influenced by each SNP. We also considered similar analyses that tested for
overrepresentation of functions, canonical pathways, and diseases among genes
that were common to a set of SNPs ranked by p value from Ingenuity. We used
the right-tailed Fisher’s exact test, as implemented in the Ingenuity software,
which assesses the number of genes in a particular list that participate in a given
pathway, relative to the total number of occurrences of those genes in all
pathways annotated by Ingenuity. In this way we could determine if sets of SNPs
appear to influence, or contribute to, the functioning of particular genetic
networks that may be associated with particular phenotypes. We identified the
drug targets in the most common network for each SNP. Since our purpose was to
capture multiple genes in a pathway affected by a given SNP, we used a less
conservative cutoff (p<0.05) to increase the probability that we would capture
the majority of effects exhibited, which could include multiple weak effects.
Multivariate distance matrix regression analysis
We took advantage of a recently introduced multivariate analysis procedure
developed by the authors [11,13,14] (C. Ye, M.A. Zapala, H.M. Kang, J. Wessel,
E. Eskin, N.J. Schork, submitted for publication). This technique, which can be
termed “multivariate distance matrix regression” analysis, involves the
construction of a distance matrix over the expression values of many genes
for the subjects in a study. The similarities and dissimilarities among the subjects
based on their gene expression profiles are then related to additional factors
collected on those subjects, such as SNP genotype information. The analysis
functions in an manner analogous to regression analysis in that the goal is to
determine the significance of the additional factors (e.g., SNPs) in “explaining”
the variation in the similarity or dissimilarity of the subjects (based on
expression profiles) represented in the distance matrix. We applied this analysis
by constructing Euclidean distance matrices for the subjects based on their
expression profiles involving genes known to participate in particular processes
or pathways and then testing to see if particular SNPs influenced the variation in
the similarity/dissimilarity of the gene expression profiles. In effect, we could
test the hypothesis that particular SNPs influence the expression profile of genes
in an entire pathway or process.Acknowledgments
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